ClinicalTrials.gg
CompletedNCT07139886Updated Aug 29, 2025

A Study to Evaluate the Safety and Efficacy of DA9601 for Acute and Chronic Gastritis and to Determine the Optimal Clinical Dosage and Administration

A Phase 2 interventional study of Stillen® Tab and Stillen® Tab Placebo in Acute Gastritis and Chronic Gastritis, sponsored by Dong-A ST Co., Ltd.. Completed at 1 site in South Korea. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-08-29.

Sponsored by Dong-A ST Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 28 years 5 months after the study started (first participant enrolled Mar 1997, registered Aug 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
212
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 32 studies in Gastritis with a site in Korea, Republic of — 3 open to participants now, 3 under way, none of them phase 3. Gastritis · Korea, Republic of.

Enrollment
16th of 25
212 · median 242
Started
1997
the only one that year
Phase 2
4 of 32
none open now
Registered
31st of 32
by date
Lead sponsor
4 of 32
Dong-A ST Co., Ltd.

Among the 32 studies in Gastritis with a site in Korea, Republic of, this one is the 16th largest by enrollment of the 25 interventional ones that give a count, is the only one that started in 1997, is one of 4 in phase 2, and was the 31st registered.

Gastritis

135 studies on the registry are indexed under Gastritis; 23 are open to participants now.

Browse Gastritis studies →

Open to participants now

3 of the 32 studies in Gastritis with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 11 Gastritis studies recruiting now, 6 (55%) set no upper age limit and 5 (45%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Gastritis with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This is a multicenter, placebo-controlled, randomized, double-blinded, paralleled group clinical study to evaluate the efficacy of 2-week treatment with DA-9601 tab in patients with acute or chronic gastritis. Subject will receive DA-9601 180mg, 360mg tab or Placebo., three times a day for two weeks.

03

Conditions studied

  • Acute Gastritis
  • Chronic Gastritis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who are diagnosed with acute gastritis and chronic gastritis by endoscopy; have gastric mucosal lesions such as erosion, bleeding, redness, swelling on the site; and have subjective and objective symptoms requiring medical treatment ② 18 years old or older, 75 years old or younger ③ Patients who have agreed with the terms of clinical trials

Exclusion criteria

Exclusion Criteria:

  • Patients with peptic ulcer (excluding scars) and reflux esophagitis

    • Patients who were administered with H2 antagonist, muscarine receptor antagonist or nonsteroidal anti-inflammatory drug within 2 weeks prior to the start of the trial

      • Patients using protective agent enhancers at the start of the trial ④ Patients with recurrence observed during maintenance therapy at the start of the trial

        • Patients with a history of gastrectomy

          • Patients with severe disorders of the liver, kidneys, heart, lungs, blood, etc. ⑦ Patients with duodenal ulcer ⑧ Patients with gastrointestinal
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
212 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    administered 2 tablets of placebo three times daily for two weeks

    Drug: Stillen® Tab Placebo

  • Experimental
    DA-9601(Stillen®) 180mg

    administered 1 tablet of placebo and 1 tablet of DA-9601(Stillen®) three times daily for two weeks

    Drug: Stillen® Tab · Drug: Stillen® Tab Placebo

  • Experimental
    DA-9601(Stillen®) 360mg

    administered 2 tablets of DA-9601(Stillen®) three times daily for two weeks

    Drug: Stillen® Tab

Interventions

  • DrugStillen® Tab

    Oral administration 3 times per day (in-between meals and before sleep) for 2 weeks

  • DrugStillen® Tab Placebo

    Oral administration 3 times per day (in-between meals and before sleep) for 2 weeks

06

What researchers measure

Primary outcomes

  1. Change in Subjective and Objective Symptoms, Gastroscopy, Overall Improvement, Effectiveness grade

    evaluated in 5 levels of "Significant improvement • Moderate improvement • Mild improvement • No improvement • Exacerbation"

    Time frame: 2 weeks

07

Study locations

1 site
  • Ajou University Medical Center, Division of Gastroenterology
    Suwon, Gyeonggi-do 16499, South Korea
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 1997 to primary completion in Jul 1999, 27 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2025
First posted
Aug 24, 2025
StartActual
Mar 14, 1997
Primary completionActual
Jul 8, 1999
CompletionActual
Jul 8, 1999
Last update
Aug 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07139886
Responsible party
Sponsor
First posted
Aug 24, 2025
Start date
Mar 14, 1997
Primary completion
Jul 8, 1999
Completion
Jul 8, 1999
Last update
Aug 29, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion